What Continuous Hormone Monitoring Means for Women
Continuous hormone monitoring is the ongoing, noninvasive measurement of key hormones through a wearable device that infers hormonal activity from physiological signals rather than blood or urine tests, giving women real-time insight into patterns that typically remain invisible between clinic visits. Clair Health is positioning its hormone tracking wearable as the first jewelry-inspired device to focus on estrogen, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) continuously. Instead of occasional lab draws, users wear a wristband that collects signals such as skin temperature, heart rate variability, and electrodermal activity, then uses AI models to interpret hormone changes. This marks a shift from single snapshots of hormone levels to a dynamic, cycle-long view. For women navigating fertility, performance, or perimenopause, it promises a more nuanced picture of physiology than standard calendars or symptom logs can offer.
Inside the $11.6M Seed Round and What It Enables
Clair Health has raised USD 11.6 million (approx. RM53.4 million) in seed funding to bring its continuous hormone monitoring wristband to market and deepen its research. The round was led by Khosla Ventures, with participation from a16z’s speedrun accelerator, Brydge Club, AI in Health Fund, Cartan Capital, AGI House, Insiders VC, and 23andMe co-founder Anne Wojcicki. The company, founded by Stanford graduates Jenny Duan and Abhinav Agarwal, plans a November launch as a wellness product, with regulatory clearance to follow. According to Clair, its waitlist has surpassed 25,000 people and the first 5,000 units sold out six months before release. The fresh funding will support scaling hardware production, refining AI models trained on more than 130 proprietary biomarkers, and advancing independent validation studies, including work through the Stanford Gladstone BeeHive program.
How Clair’s Noninvasive Hormone-Tracking Wearable Works
Clair’s hormone tracking wearable uses a stack of ten biosensors, including biomagnetic sensors, to read subtle changes in the body and infer hormone levels. These sensors measure signals like skin temperature, heart rate variability, and electrodermal activity, which Clair’s AI maps to patterns in estrogen, progesterone, LH, and FSH. The company reports that its models can classify menstrual cycle phases with 94% accuracy when compared to daily urine samples, though peer-reviewed clinical data has not yet been published. Clair also holds provisional patents on its sensor configuration and is experimenting with voice-based biomarkers that may identify cycle phases after a short conversation. Data privacy is a core design feature: processing happens on the user’s phone, and the company says information is protected with zero-knowledge encryption to keep sensitive hormonal data under the user’s control.
Revealing New Complexity in Female Physiology
Clair’s continuous hormone monitoring data suggests that the menstrual cycle is more complex than the standard four-phase model often taught. In beta testing, the company reports identifying nine distinct sub-phases, hinting at subtle hormonal transitions that may influence mood, energy, fertility, and physical performance. Co-founder Jenny Duan notes that while wearables already track heart rate variability, sleep, steps, and breathing, those metrics in women are strongly shaped by hormones. By adding noninvasive hormone tracking, Clair aims to connect those dots and highlight how shifting estrogen and progesterone levels modulate other signals. The data could inform timing for fertility and conception, flag hormonal conditions such as PCOS, and help women adjust training or recovery. As Duan puts it, “The data has always been there; we just haven’t had something to read it until now.”
A Fashion-Forward Future for Women’s Health Wearables
Clair is entering a crowded women’s health wearables market at a time when 57% of people reportedly own a wearable or connected device, making differentiation essential. Its jewelry-inspired design aims to reposition noninvasive hormone tracking as both a health tool and a daily accessory, moving away from medicalized aesthetics toward something users feel comfortable wearing around the clock. The wristband is planned as a wellness product first, with a subscription model and future features that could cover perimenopause monitoring, hormone replacement therapy fine-tuning, and screening support for conditions like PCOS and endometriosis. More than 100 fertility clinics have signaled interest through letters of intent, suggesting potential clinical partnerships down the line. If Clair can prove accuracy in peer-reviewed studies and maintain user trust on privacy, its continuous hormone monitoring approach may set a new baseline for how wearables serve women’s long-term health.
